Cumberland Pharmaceuticals

Company snapshot

Cumberland Pharmaceuticals maintains 53 tracked programs across Pain, Hyponatremia, Fever, Colonoscopy Preparation, Kidney Diseases, Acetaminophen Overdose, Glioblastoma, Hypercholesterolemia, Burns, Chronic Heart Failure, Liver Disease, Liver Cirrhosis. Momentum score: 24/100 (30-day delta: n/a). Public registry data covers pipeline phase, clinical trials, patents, SEC filings, and Nova editorial

• 2 approved product(s) across US/EU regulatory metadata.
• 53 active pipeline program(s) linked via ClinicalTrials.gov.
• 34 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Cumberland Pharmaceuticals. Not investment advice.

• approval Jun 2, 2026

  Cumberland Pharmaceuticals (NASDAQ: CPIX) to divest marketed brands to Apotex for $100M

• Peer + 0 momentum

  MSD Merck Sharp

  TA overlap score 40

Recent activity

Latest pipeline, patent, and corporate events for Cumberland Pharmaceuticals.

1. Jun 8, 2026 Clinical update

   Telavancin Injection — Approved

2. Jun 8, 2026 Clinical update

   Telavancin Injection — Approved

3. Jun 8, 2026 Clinical update

   Telavancin — Phase 3

4. Jun 8, 2026 Clinical update

   Ofirmev — Approved

5. Jun 8, 2026 Clinical update

   N-Acetylcysteine (NAC) — Phase 2

View all clinical trial activity →

• What is Cumberland Pharmaceuticals?

  Cumberland Pharmaceuticals is a pharma organization headquartered in Nashville, USA. It trades on NYSE under ticker CPIX. Primary therapeutic focus areas include Pain, Hyponatremia, Fever, Colonoscopy Preparation, Kidney Diseases. NovaPharmaNews links 53 clinical program(s), 2 dr

• Is Cumberland Pharmaceuticals publicly traded?

  Yes. Cumberland Pharmaceuticals is listed with ticker CPIX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Cumberland Pharmaceuticals develop or market?

  We link 26 drug profile(s) where Cumberland Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/cumberland-pharmaceuticals-inc#company-drugs.

• What are the latest developments for Cumberland Pharmaceuticals?

  In the last 12 months our linked public records show 53 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Cumberland Pharmaceuticals focus on?

  Cumberland Pharmaceuticals focuses on Pain, Hyponatremia, Fever based on our analysis of their pipeline programs and drug development activities.